contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


increase-of-the-number-of-shares-and-votes-in-hansa-biopharma-ab

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Hansa Biopharma er en svensk biotekvirksomhed imlifidase (Idefirix) som hovedproduktet. Imlifidase er et antistof-spaltende enzym, der udvikles til at muliggøre nyretransplantation hos stærkt sensibiliserede patienter. Enzymet kan videreudvikles til brug ved andre typer transplantation, i autoimmune sygdomme, genterapi og onkologi. Hidtil er Idefirix blevet betinget godkendt i EU til højsensibiliserede nyretransplanterede patienter.

I øjeblikket udfører Hansa et afgørende randomiseret kontrolforsøg i nyretransplantation i USA og forventer at påbegynde et yderligere afgørende studie på tværs af USA og EU i den sjældne autoimmune sygdom anti-GBM i løbet af 2022. Derudover fremmer Hansas forsknings- og udviklingsprogram enzymteknologien til at udvikle den næste generation af IgG-spaltende enzymer med potentielt lavere immunogenicitet, velegnet til gentagende dosering ved recidiverende autoimmune sygdomme og onkologi.

Kære forum  Hvis der er nogle af jer som har kendskab til Hansa Biopharma, så meld gerne ind med input  Jeg har selv noget kendskab til Hansa Biopharma og et firma som jeg forventer en god performance af og at de bliver lønsomme fremad og hvis det går som forventede med deres produkt lansering

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  Hansa Biopharma er en svensk biotekvirksomhed imlifidase (Idefirix) som hovedproduktet. Imlifidase er et antistof-spaltende enzym, der udvikles til at muliggøre nyretransplantation hos stærkt sensibiliserede patienter. Enzymet kan videreudvikles til brug ved andre typer transplantation, i autoimmune sygdomme, genterapi og onkologi. Hidtil er Idefirix blevet betinget godkendt i EU til højsensibiliserede nyretransplanterede patienter. I øjeblikket udfører Hansa et afgørende randomiseret kontrolforsøg i nyretransplantation i USA og forventer at påbegynde et yderligere afgørende studie på tværs af USA og EU i den sjældne autoimmune sygdom anti-GBM i løbet af 2022. Derudover fremmer Hansas forsknings- og udviklingsprogram enzymteknologien til at udvikle den næste generation af IgG-spaltende enzymer med potentielt lavere immunogenicitet, velegnet til gentagende dosering ved recidiverende autoimmune sygdomme og onkologi. English:  Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized control trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM in 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

Hansa Biopharma

Lund, Sweden, December 30, 2021. Hansa Biopharma AB "Hansa" or "the Company", (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that ...

<div class="abstract"><p>Lund, Sweden, December 30, 2021. Hansa Biopharma AB&nbsp;"Hansa" or "the Company", (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the Company's registered share capital and number of outstanding shares and votes have increased during the month of December 2021.</p></div><p>As previously announced on 12 December 2021, Hansa Biopharma's board of directors resolved to issue 440,452 class C shares, by virtue of the authorization by the annual general meeting held on 12 May 2021. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.</p><p>The purpose of the share issue and the repurchase of the issued shares is to enable potential future delivery of ordinary shares in accordance with long term incentive programs based on employee stock options adopted by the annual general meeting held on 23 June 2020 and the annual general meeting held on 12 May 2021 as well as to cover any social charges associated with the mentioned, or other outstanding, programs. All class C shares are owned by the Company.</p><p>As of today, the total number of registered and outstanding shares of the Company amounts to 46,335,361, whereof 44,473,452 are ordinary shares and 1,861,909 are class C shares. As of today, the number of votes in the Company amounts to 44,659,642.9, and the registered share capital amounts to SEK 46,335,361.</p>